Switch to public / patients Icon Arrow Right
Shop HCP Login
Home > HCP > Clinical Efficacy

Clinical Efficacy

The efficacy of GelX® Oral Spray has been evaluated 
and proven in a number of clinical studies.

Niculita et al, 2020 5

The Efficacy of Polyvinylpyrrolidone- Zn Gluconate and Taurine (GelX®) in the prevention of Oral Mucositis in Haematological Patients.

Results

A study of 145 patients made up of 99 adults (68.27%) and 46 children (31.72%). All 145 patients received GelX® Oral Spray for preventing OM.

  • The prevention of OM was achieved in 54 patients (37.24%) [22 adults, 32 children] where patients developed no OM at all.
  • In the remaining patients who developed symptoms of OM, 93.4% had a complete remission of symptoms.
Icon Download Download clinical guide

Colita et al, 20156

The Efficacy of Polyvinylpyrrolidone-Zinc Gluconate and Taurine Gel (GelX®) 
in Prophylaxis and Treatment of Oral Mucositis in Children Treated with Chemotherapy.

Results

GelX® Oral Spray was administered 
prophylactically or as a curative in this study.

  • There was no difference in the median value 
of tolerability of GelX® between the 2 groups.
  • In the prophylaxis arm, there was a significant reduction of OM 
severity with better results in quality of life, pain control and oral intake.
Icon Download Download clinical guide

Dragomir et al, 20157

The Efficacy of Polyvinylpyrrolidone-Zinc Gluconate and Taurine Gel (GelX®) 
in Prevention and Treatment of Chemotherapy-Induced Oral Mucositis in Children with Cancer.

Results

GelX® Oral Spray in Prevention and Treatment of Chemotherapy-induced Oral Mucositis in Children with Cancer.

  • Pain was reduced in 80% of patients after the treatment with GelX® Oral Spray.
  • Swallowing difficulties were reduced in 74% of patients
  • There were no delays in treatment caused by severity of OM
  • It was concluded that GelX® Oral Spray prevents severe mucositis and promotes healing
Icon Download Download clinical guide

Zannier et al, 201916

Effects of Three Products in the Prevention and Treatment of Chemotherapy and Radiation Therapy-induced Oral Mucositis.

Results

Sixty adult patients were randomised into 3 arms to receive either GelX® Oral Spray (Group 1), Episil Oral Solution (Group 2) or Gelclair Oral Gel (Group 3).

  • The GelX® Oral Spray group demonstrated an overall better efficacy and grade of safety compared to the other two groups.
Icon Download Download clinical guide

Trusted by patients & healthcare professionals…

I started using GelX after 1 cycle of chemotherapy. I had already started with a number of large mouth ulcers and was finding eating and swallowing painful. After just 2 days of using GelX, no further ulcers appeared. Throughout my chemo treatments I only had a handful of small ulcers. I can wholeheartedly say that GelX has made a significant difference to my oral comfort and enabled me to eat more normally than I could have done…A truly wonderful product!

Jayne, Patient, Wrexham

I was kindly sent GelX at the beginning of my throat cancer journey. During treatment this was a fantastic product that enabled me to have a life. Eating, drinking, smiling - GelX played a big part. I would 100% fully recommend this product to anybody without hesitation.

Jon, Patient, Surrey

I support patients with Head and Neck cancers and have found, since the introduction of GelX during radiotherapy (with or without chemotherapy), mucositis is reduced. This has meant for some patients, stronger analgesics have not been necessary or at least not required so early on during their course of radiotherapy. We find using GelX prophylactically in Head and Neck cancer patients, receiving radiotherapy, helps reduce the severity of mucositis.

Head & Neck Specialist Radiographer, Kent

We have been using GelX for about a year now. Mucositis has been improved in patients who use it consistently from the beginning of treatment.

Dr. Jennifer Turner, Consultant Clinical Oncologist

All Testimonials
Icon References View References
References & Reporting of Adverse Incidents >